PSTI - Pluristem Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.26
+0.02 (+1.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.24
Open1.24
Bid1.24 x 21500
Ask1.30 x 1100
Day's Range1.21 - 1.26
52 Week Range1.06 - 2.12
Volume125,636
Avg. Volume572,760
Market Cap139.695M
Beta1.38
PE Ratio (TTM)N/A
EPS (TTM)-0.24
Earnings DateFeb 15, 2018 - Feb 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.83
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    U.S. Department of Defense to Study Pluristem’s PLX-R18 for the Treatment of Mustard Gas Injuries

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today it has entered into an additional collaboration agreement with the U.S. Department of Defense (DOD) and its United States Army Medical Research Institute of Chemical Defense (USAMRICD) to study the Company’s PLX-R18 cell therapy product in the treatment of long term lung injuries following exposure to mustard gas. The DOD is also studying the effectiveness of PLX-R18 as a novel medical countermeasure for Acute Radiation Syndrome (ARS) prior to exposure to high levels of radiation, designed to support the needs of the U.S. Armed Forces.

  • GlobeNewswire8 days ago

    Pluristem to Open Weekly Market Trading at TASE Following Positive Study Results

    HAIFA, Israel, June 14, 2018-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, is delighted to announce that it has been invited by the Tel Aviv Stock Exchange ...

  • Should You Be Content With Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Earnings Growth?
    Simply Wall St.9 days ago

    Should You Be Content With Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Earnings Growth?

    In this article, I will take a look at Pluristem Therapeutics Inc’s (NASDAQ:PSTI) most recent earnings update (31 March 2018) and compare these latest figures against its performance over theRead More...

  • Benzinga10 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Pluristem Therapeutics Inc. (NASDAQ: PSTI ) stock ...

  • Reuters10 days ago

    Israel's Pluristem sees positive results from leg pain study

    Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent ...

  • GlobeNewswire10 days ago

    Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, today announced positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication (IC). PLX-PAD treatment reduced Incidence of revascularization and improved patients’ mobility. Study results also validate the design of Pluristem’s ongoing Pivotal Phase III study in CLI, a more severe stage of peripheral arterial disease (PAD) and confirm Pluristem’s proprietary Bio-Therapeutic approach.

  • Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock
    Zacks17 days ago

    Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock

    Investors in Pluristem Therapeutics (PSTI) need to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswire18 days ago

    Pluristem to Announce Top-Line Results of Its Multinational Phase II Intermittent Claudication Study on June 12, 2018

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, today announced that the top-line results of the company’s multinational Phase II clinical trial of PLX-PAD cells in the treatment of Intermittent Claudication (IC) will be released on June 12, 2018. Pluristem's Phase II IC trial is evaluating the safety and efficacy of PLX-PAD cells as compared to placebo in 172 patients with IC, Rutherford category 2-3.

  • Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic?
    Simply Wall St.last month

    Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic?

    Pluristem Therapeutics Inc’s (NASDAQ:PSTI): Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The US$156.33M market-cap posted a loss in its most recentRead More...

  • Associated Presslast month

    Pluristem: Fiscal 3Q Earnings Snapshot

    The Haifa, Israel-based company said it had a loss of 1 cent per share. The company's shares closed at $1.33. A year ago, they were trading at $1.32. _____ This story was generated by Automated Insights ...

  • GlobeNewswirelast month

    Pluristem Reports Third Quarter Fiscal 2018 Corporate and Financial Highlights

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, today reported financial results and corporate developments for its third quarter of fiscal 2018 ended March 31, 2018. “The past few months brought several significant milestones which we believe are key to our continued development”, stated Pluristem Chairman and Co-CEO Zami Aberman. “The U.S. Food and Drug Administration (FDA) has cleared our Investigational New Drug application (IND) for the use of PLX-R18 in treating victims who may have been acutely exposed to high dose radiation (ARS) due to nuclear attack or accident.

  • Benzinga2 months ago

    FDA Clears New Drug Application For Pluristem's PLX-R18; What's Next?

    Pluristem Therapeutics Inc. (NASDAQ: PSTI ), which develops placenta-based cell therapy products, announced Monday that the FDA cleared an investigational new drug application for PLX-R18 cell therapy ...

  • Benzinga2 months ago

    Benzinga Pro's 6 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Allergan plc (NYSE: AGN ) stock was trading higher ...

  • GlobeNewswire2 months ago

    U.S. FDA Clears Pluristem’s IND to Treat Victims Exposed to Acute Radiation

    HAIFA, Israel, April 30, 2018-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that the U.S. Food and Drug Administration has cleared the Company’ ...

  • Reuters2 months ago

    FDA clears Pluristem radiation treatment for emergency use

    Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event. Pluristem said it will start preparations to keep an emergency stock of PLX-R18 on hand for use in such events. Full approval of the drug will depend on the results of a Phase III clinical trial.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! MannKind Corporation (NASDAQ: MNKD ) stock was trading ...

  • GlobeNewswire2 months ago

    U.S. FDA Clears Pluristem’s Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that the U.S. Food and Drug Administration (FDA) has cleared Pluristem’s Investigational Drug Application (IND) for a Phase III study of its PLX-PAD cell therapy in the treatment of muscle injury following surgical repair (arthroplasty) of the hip joint due to fracture. Pluristem is in discussions with several EU countries to approve this study in Europe as well and expects to begin patient enrollment in both regions during 2018. The Phase III study follows positive results from a Phase I/II trial which demonstrated significant muscle regeneration when using PLX-PAD cells in total hip arthroplasty patients.

  • GlobeNewswire2 months ago

    Pluristem and Indiana University to Initiate Joint Project Evaluating PLX-R18 in Acute Radiation Syndrome, Targeting Bridging Data for Pivotal Study

    The 5- year joint project was granted $2.5 million from the U.S. National Institutes of Health Data from these studies will support BLA filing for marketing approval of PLX-R18 in the treatment of ARS ...

  • GlobeNewswire3 months ago

    Roger Jeffs, Former Co-CEO of United Therapeutics, Joins Pluristem's Strategic Advisory Board

    HAIFA, Israel, March 26, 2018-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that Dr. Roger Jeffs has joined Pluristem’ s strategic advisory ...

  • What You Must Know About Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Major Investors
    Simply Wall St.4 months ago

    What You Must Know About Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Major Investors

    I am going to take a deep dive into Pluristem Therapeutics Inc’s (NASDAQ:PSTI) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...

  • Reuters5 months ago

    N.Korea threats spur U.S. search for new radiation therapies

    The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome. The hostility between the two nations reached a new height last November after Pyongyang fired an intercontinental ballistic missile capable of reaching the U.S. mainland. The DoD's budget allocated $3.9 million of its total funding to develop such medical countermeasures in 2018, an increase of $600,000 from a year ago.

  • ACCESSWIRE5 months ago

    Wired News – Pluristem’s PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed Article

    Stock Monitor: CEL-SCI Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 17, 2018 / Active-Investors.com has just released a free research report on Pluristem Therapeutics Inc. (NASDAQ: PSTI ). ...